North America Antimicrobial Susceptibility Testing Market

North America Antimicrobial Susceptibility Testing Market Size (2023 to 2028)

The North American market size for antimicrobial susceptibility testing is forecasted to be growing at a CAGR of 5.86% from 2023 to 2028 and be worth USD 2.03 billion by 2028 from USD 1.52 billion in 2023.

The rising prevalence of hospital-acquired infections (HAIs), a growing patient population, and increased government awareness of the need to fight antimicrobial resistance are expected to fuel the market even further. Antimicrobial susceptibility testing is becoming more important as the frequency of multidrug-resistant infections rises. In addition, rising awareness programs and initiatives for customized medicine have a favorable impact on market growth. Increasing the usage of antimicrobial susceptibility testing by pharmaceutical companies is another key element driving the market forward. The automated antimicrobial susceptibility test devices come with various modern features and functions, and they're reasonably priced. In addition, the incubation and detection times are halved when using automated Antimicrobial Susceptibility Test techniques.

Furthermore, public health, a top priority for governments in the region, has been found to have a favorable impact on public-private partnerships in the region. This is also expected to be used to help market players accelerate the pace of product development. Increased use of antimicrobial susceptibility testing by biopharmaceutical, biotechnological, and pharmaceutical companies is a significant factor for the considerable growth of the North American antimicrobial susceptibility testing market, owing to a growing emphasis on drug discovery, the emergence of new diseases, as well as the increasing incidences of chronic disorders. In addition, the availability of various manual and automated products that provide testing results in less time with better accuracy is an emerging opportunity for key market players to invest in the antimicrobial susceptibility testing market, which will accelerate market expansion and provide significant growth potential for the market during the forecast period.

The expensive cost of these systems, particularly for small-budget organizations, is a key impediment to their widespread adoption by end-users. Furthermore, the market is expected to be restrained by strict regulatory government policies and the hurdles involved with antimicrobial susceptibility testing over the forecast period. This makes antibacterial medications less profitable for pharmaceutical corporations. This lack of return on investment restricts the market's expansion.

This research report on the North American antimicrobial susceptibility testing market has been segmented and sub-segmented into the following categories.

By Product:

• Manual Antimicrobial Susceptibility Testing Products
  • Susceptibility Testing Disks
  • MIC Strips
  • Susceptibility Testing Plates
• Automated Laboratory Instruments
• Culture and Growth Media
• Consumables

 By Application:

• Clinical Diagnostics
• Drug Discovery and Development
• Epidemiology

By End-User:

• Hospitals and Diagnostic Centers
• Pharmaceutical and Biotechnology Companies
• Research &Academic Institutes
• Clinical Research Organizations

By Country:

• The United States
• Canada
• Rest of North America

Because of increased investments in developing novel testing methods, North America is likely to lead the market. Because of the surge in epidemic and pandemic occurrences and the availability of advanced healthcare infrastructure, the United States dominates the North American market. North America is expected to dominate the global antimicrobial susceptibility testing market throughout the projected period. This is attributable to several factors, including an increase in antibiotic-resistant diseases in the region. Increased R&D to develop novel automated AST systems, rising prevalence of infectious diseases, safety concerns, and technological improvements in antimicrobial susceptibility products are all driving market expansion in North America. The U.S. government will take several steps to combat drug-resistant diseases, necessitating the development and deployment of fast diagnostics. Such innovations are boosting the market's growth in North America. As a result, the United States will contribute the most revenue to the market in North America.

KEY MARKET PLAYERS:

Companies playing a prominent role in the North American antimicrobial susceptibility testing market profiled in this report are Danaher Corporation, Becton, Dickinson, and Company., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merlin Diagnostika GmbH, bioMerieux S.A., Merck KGaA, Accelerate Diagnostics, Inc., and Creative Diagnostics.